Dry eye disease is growing rapidly, yet many practices still lack an efficient, affordable way to screen patients. Traditional diagnostic setups are costly, space-consuming, and difficult to deploy outside the clinic—making it hard for new practices to start a dry eye service and for established practices to expand community outreach. As a result, early signs of meibomian gland dysfunction are often missed, workflow becomes fragmented, and practices lose opportunities to deliver comprehensive care.